Sorrento closes Virttu Bio buy

|About: Sorrento Therapeutics,... (SRNE)|By:, SA News Editor

Sorrento Therapeutics (SRNE -2.4%) finalizes its all-stock acquisition of Glasgow, Scotland-based Virttu Biologics. Virttu shareholders received 797,081 SRNE common shares based on a price of $5.55.

Previously: Sorrento subsidiary to acquire Scottish biotech Virttu Biologics for $25M in all-stock deal (Nov. 16, 2016)